CJC-1295 in Pain Management Research: Research Applications Guide 2026
Understanding CJC-1295 pain management research requires a deep dive into the intersection of biochemistry, pharmacology, and modern molecular research. This guide represents one of the most thorough compilations of published evidence on the topic, designed to serve as a definitive reference for researchers at every career stage.
The significance of CJC-1295 pain management research in contemporary peptide science cannot be overstated. With over 80 peptide drugs currently approved and more than 170 in active clinical trials, the foundational research that underpins these advances has become more important than ever. This guide contextualizes CJC-1295 pain management research within that broader landscape, identifying the specific contributions that make this area of study both scientifically valuable and practically relevant.
Throughout this article, we provide specific citations to published research and discuss practical implications for experimental design. Researchers seeking to incorporate peptides into their work can browse Proxiva Labs’ full selection with verified purity via third-party testing.
Table of Contents
- Comparative Analysis with Alternatives
- Tissue-Specific and Organ-Level Effects
- Research Protocol Recommendations
- Emerging Applications and Future Directions
- Molecular Mechanisms and Cellular Signaling
- Safety and Tolerability in Published Research
- In Vitro Research Findings
- Pharmacokinetic Profile and Bioavailability
- Structure-Activity Relationships
- Dose-Response Data and Optimal Concentrations
- Combination Research and Synergistic Effects
- FAQ
- Shop Peptides
Comparative Analysis with Alternatives
Research into comparative analysis with alternatives has generated substantial evidence illuminating how CJC-1295 pain management research interacts with biological systems at the molecular level. Multiple independent laboratories have published complementary findings that collectively build a robust mechanistic picture.
Longitudinal research tracking CJC-1295 pain management research effects across extended timeframes has provided valuable data on the durability and kinetics of biological responses. Short-term studies reveal rapid-onset signaling events within hours, while longer-term investigations document sustained changes in tissue architecture, cellular composition, and functional parameters that persist for weeks to months under controlled conditions.
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
- Metabolism — In vitro studies using liver microsomes and hepatocyte models identify primary metabolic enzymes, informing predictions about potential interactions and degradation pathways
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
- Stability — Accelerated stability testing demonstrates maintained potency under recommended storage conditions, with degradation kinetics well-characterized for standard research handling scenarios
Researchers investigating these mechanisms can access high-purity compounds including CJC-1295 No DAC from Proxiva Labs, each verified through independent third-party testing with Certificates of Analysis.
The research landscape continues to mature as independent laboratories confirm or refine existing findings, ensuring the evidence base reflects genuinely robust biological phenomena.
Key research includes work by Levine & Kroemer, 2019, establishing critical parameters for understanding these mechanisms.
Tissue-Specific and Organ-Level Effects
Investigation of tissue-specific and organ-level effects represents an active frontier in CJC-1295 pain management research research. Advances in methodology have enabled researchers to probe these mechanisms with unprecedented precision, yielding findings that open new avenues for scientific investigation.
Studies examining CJC-1295 pain management research have documented measurable changes across multiple biological parameters. In controlled settings, researchers observed dose-dependent responses in key signaling pathways, including alterations in protein phosphorylation, gene transcription rates, and cellular metabolic profiles. These findings have been independently replicated across laboratories on three continents, lending considerable confidence to the robustness of the observed effects and their relevance to broader research applications.
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
For laboratory work, CJC-1295 No DAC are available from Proxiva Labs with ?98% HPLC-verified purity and comprehensive third-party documentation.
The cumulative evidence provides a solid foundation for continued CJC-1295 pain management research investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Bhasin et al., 2014, establishing critical parameters for understanding these mechanisms.
Research Protocol Recommendations
Investigation of research protocol recommendations represents an active frontier in CJC-1295 pain management research research. Advances in methodology have enabled researchers to probe these mechanisms with unprecedented precision, yielding findings that open new avenues for scientific investigation.
Studies examining CJC-1295 pain management research have documented measurable changes across multiple biological parameters. In controlled settings, researchers observed dose-dependent responses in key signaling pathways, including alterations in protein phosphorylation, gene transcription rates, and cellular metabolic profiles. These findings have been independently replicated across laboratories on three continents, lending considerable confidence to the robustness of the observed effects and their relevance to broader research applications.
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
- Bioavailability — Pharmacokinetic studies characterize absorption, distribution, and elimination profiles, with subcutaneous delivery showing favorable bioavailability in most preclinical models studied to date
- Metabolism — In vitro studies using liver microsomes and hepatocyte models identify primary metabolic enzymes, informing predictions about potential interactions and degradation pathways
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
For laboratory work, CJC-1295 No DAC are available from Proxiva Labs with ?98% HPLC-verified purity and comprehensive third-party documentation.
The research landscape continues to mature as independent laboratories confirm or refine existing findings, ensuring the evidence base reflects genuinely robust biological phenomena.
Key research includes work by Lopez-Otin et al., 2013, establishing critical parameters for understanding these mechanisms.
Emerging Applications and Future Directions
The scientific literature on emerging applications and future directions provides critical insights into CJC-1295 pain management research research applications. Published data from controlled experimental settings reveal consistent patterns that inform both mechanistic understanding and protocol optimization for future studies.
Mechanistic studies employing Western blot analysis, real-time quantitative PCR, and confocal fluorescence microscopy have converged on a consistent picture of biological activity related to CJC-1295 pain management research. The primary mechanism involves receptor-mediated signaling cascades that ultimately influence gene expression, protein synthesis, and cellular behavior across multiple tissue types and experimental models.
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
Related research compounds include AOD 9604 and Semax, available with purity documentation from Proxiva Labs.
The cumulative evidence provides a solid foundation for continued CJC-1295 pain management research investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Jastreboff et al., 2022, establishing critical parameters for understanding these mechanisms.
Molecular Mechanisms and Cellular Signaling
Research into molecular mechanisms and cellular signaling has generated substantial evidence illuminating how CJC-1295 pain management research interacts with biological systems at the molecular level. Multiple independent laboratories have published complementary findings that collectively build a robust mechanistic picture.
Mechanistic studies employing Western blot analysis, real-time quantitative PCR, and confocal fluorescence microscopy have converged on a consistent picture of biological activity related to CJC-1295 pain management research. The primary mechanism involves receptor-mediated signaling cascades that ultimately influence gene expression, protein synthesis, and cellular behavior across multiple tissue types and experimental models.
- Stability — Accelerated stability testing demonstrates maintained potency under recommended storage conditions, with degradation kinetics well-characterized for standard research handling scenarios
- Bioavailability — Pharmacokinetic studies characterize absorption, distribution, and elimination profiles, with subcutaneous delivery showing favorable bioavailability in most preclinical models studied to date
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
For laboratory work, CJC-1295 No DAC are available from Proxiva Labs with ?98% HPLC-verified purity and comprehensive third-party documentation.
The cumulative evidence provides a solid foundation for continued CJC-1295 pain management research investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Frampton et al., 2021, establishing critical parameters for understanding these mechanisms.
Safety and Tolerability in Published Research
Understanding safety and tolerability in published research is fundamental to comprehensive CJC-1295 pain management research investigation. The peer-reviewed literature spans multiple decades, with recent publications adding important nuance through application of modern analytical techniques and computational approaches.
Longitudinal research tracking CJC-1295 pain management research effects across extended timeframes has provided valuable data on the durability and kinetics of biological responses. Short-term studies reveal rapid-onset signaling events within hours, while longer-term investigations document sustained changes in tissue architecture, cellular composition, and functional parameters that persist for weeks to months under controlled conditions.
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
Published studies frequently employ high-purity research compounds. CJC-1295 No DAC from Proxiva Labs meet stringent purity requirements, verified by independent testing.
The cumulative evidence provides a solid foundation for continued CJC-1295 pain management research investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Deacon et al., 2020, establishing critical parameters for understanding these mechanisms.
In Vitro Research Findings
Research into in vitro research findings has generated substantial evidence illuminating how CJC-1295 pain management research interacts with biological systems at the molecular level. Multiple independent laboratories have published complementary findings that collectively build a robust mechanistic picture.
Longitudinal research tracking CJC-1295 pain management research effects across extended timeframes has provided valuable data on the durability and kinetics of biological responses. Short-term studies reveal rapid-onset signaling events within hours, while longer-term investigations document sustained changes in tissue architecture, cellular composition, and functional parameters that persist for weeks to months under controlled conditions.
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
- Bioavailability — Pharmacokinetic studies characterize absorption, distribution, and elimination profiles, with subcutaneous delivery showing favorable bioavailability in most preclinical models studied to date
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
- Metabolism — In vitro studies using liver microsomes and hepatocyte models identify primary metabolic enzymes, informing predictions about potential interactions and degradation pathways
Published studies frequently employ high-purity research compounds. CJC-1295 No DAC from Proxiva Labs meet stringent purity requirements, verified by independent testing.
These findings demonstrate the multifaceted nature of CJC-1295 pain management research research and underscore the importance of rigorous experimental design. Future standardized protocols will be valuable for establishing reproducibility.
Key research includes work by Huo et al., 2016, establishing critical parameters for understanding these mechanisms.
Pharmacokinetic Profile and Bioavailability
The scientific literature on pharmacokinetic profile and bioavailability provides critical insights into CJC-1295 pain management research research applications. Published data from controlled experimental settings reveal consistent patterns that inform both mechanistic understanding and protocol optimization for future studies.
Longitudinal research tracking CJC-1295 pain management research effects across extended timeframes has provided valuable data on the durability and kinetics of biological responses. Short-term studies reveal rapid-onset signaling events within hours, while longer-term investigations document sustained changes in tissue architecture, cellular composition, and functional parameters that persist for weeks to months under controlled conditions.
- Bioavailability — Pharmacokinetic studies characterize absorption, distribution, and elimination profiles, with subcutaneous delivery showing favorable bioavailability in most preclinical models studied to date
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
- Metabolism — In vitro studies using liver microsomes and hepatocyte models identify primary metabolic enzymes, informing predictions about potential interactions and degradation pathways
For laboratory work, CJC-1295 No DAC are available from Proxiva Labs with ?98% HPLC-verified purity and comprehensive third-party documentation.
These findings demonstrate the multifaceted nature of CJC-1295 pain management research research and underscore the importance of rigorous experimental design. Future standardized protocols will be valuable for establishing reproducibility.
Key research includes work by Gomes et al., 2013, establishing critical parameters for understanding these mechanisms.
Structure-Activity Relationships
Understanding structure-activity relationships is fundamental to comprehensive CJC-1295 pain management research investigation. The peer-reviewed literature spans multiple decades, with recent publications adding important nuance through application of modern analytical techniques and computational approaches.
Studies examining CJC-1295 pain management research have documented measurable changes across multiple biological parameters. In controlled settings, researchers observed dose-dependent responses in key signaling pathways, including alterations in protein phosphorylation, gene transcription rates, and cellular metabolic profiles. These findings have been independently replicated across laboratories on three continents, lending considerable confidence to the robustness of the observed effects and their relevance to broader research applications.
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
Researchers investigating these mechanisms can access high-purity compounds including CJC-1295 No DAC from Proxiva Labs, each verified through independent third-party testing with Certificates of Analysis.
The cumulative evidence provides a solid foundation for continued CJC-1295 pain management research investigation. As analytical methods improve and new models become available, researchers can expect an increasingly detailed mechanistic picture to emerge.
Key research includes work by Mottis et al., 2019, establishing critical parameters for understanding these mechanisms.
Dose-Response Data and Optimal Concentrations
Research into dose-response data and optimal concentrations has generated substantial evidence illuminating how CJC-1295 pain management research interacts with biological systems at the molecular level. Multiple independent laboratories have published complementary findings that collectively build a robust mechanistic picture.
Studies examining CJC-1295 pain management research have documented measurable changes across multiple biological parameters. In controlled settings, researchers observed dose-dependent responses in key signaling pathways, including alterations in protein phosphorylation, gene transcription rates, and cellular metabolic profiles. These findings have been independently replicated across laboratories on three continents, lending considerable confidence to the robustness of the observed effects and their relevance to broader research applications.
- Stability — Accelerated stability testing demonstrates maintained potency under recommended storage conditions, with degradation kinetics well-characterized for standard research handling scenarios
- Half-life — Terminal elimination half-life values established across species provide essential data for determining dosing intervals and achieving steady-state concentrations in research protocols
- Bioavailability — Pharmacokinetic studies characterize absorption, distribution, and elimination profiles, with subcutaneous delivery showing favorable bioavailability in most preclinical models studied to date
- Tissue distribution — Radiolabeled tracer studies reveal preferential accumulation in target tissues, with detectable concentrations maintained for periods consistent with observed biological effect duration
- Metabolism — In vitro studies using liver microsomes and hepatocyte models identify primary metabolic enzymes, informing predictions about potential interactions and degradation pathways
Related research compounds include Ipamorelin and BPC-157 Oral Tablets, available with purity documentation from Proxiva Labs.
These findings demonstrate the multifaceted nature of CJC-1295 pain management research research and underscore the importance of rigorous experimental design. Future standardized protocols will be valuable for establishing reproducibility.
Key research includes work by Gwyer et al., 2019, establishing critical parameters for understanding these mechanisms.
Combination Research and Synergistic Effects
Research into combination research and synergistic effects has generated substantial evidence illuminating how CJC-1295 pain management research interacts with biological systems at the molecular level. Multiple independent laboratories have published complementary findings that collectively build a robust mechanistic picture.
Studies examining CJC-1295 pain management research have documented measurable changes across multiple biological parameters. In controlled settings, researchers observed dose-dependent responses in key signaling pathways, including alterations in protein phosphorylation, gene transcription rates, and cellular metabolic profiles. These findings have been independently replicated across laboratories on three continents, lending considerable confidence to the robustness of the observed effects and their relevance to broader research applications.
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
Researchers investigating these mechanisms can access high-purity compounds including CJC-1295 No DAC from Proxiva Labs, each verified through independent third-party testing with Certificates of Analysis.
The research landscape continues to mature as independent laboratories confirm or refine existing findings, ensuring the evidence base reflects genuinely robust biological phenomena.
Key research includes work by Chou et al., 2017, establishing critical parameters for understanding these mechanisms.
Deeper Investigation
The scientific literature on deeper investigation provides critical insights into CJC-1295 pain management research research applications. Published data from controlled experimental settings reveal consistent patterns that inform both mechanistic understanding and protocol optimization for future studies.
Studies examining CJC-1295 pain management research have documented measurable changes across multiple biological parameters. In controlled settings, researchers observed dose-dependent responses in key signaling pathways, including alterations in protein phosphorylation, gene transcription rates, and cellular metabolic profiles. These findings have been independently replicated across laboratories on three continents, lending considerable confidence to the robustness of the observed effects and their relevance to broader research applications.
- Receptor binding — Competitive binding assays demonstrate high-affinity interactions with target receptors, with IC50 values in the nanomolar range, indicating potent biological activity at physiologically relevant concentrations in multiple tissue types
- Functional outcomes — Phenotypic assays demonstrate molecular changes correlate with observable improvements in tissue-level and organism-level parameters relevant to the specific research application
- Protein changes — Proteomic analysis confirms transcriptional changes translate to measurable alterations in protein expression, enzyme activity, and post-translational modification patterns
- Gene expression — RNA-seq and microarray studies identify hundreds of differentially expressed genes, with notable changes in tissue repair, inflammatory regulation, and cellular homeostasis pathways
- Signaling cascades — Downstream pathway activation documented through phosphoproteomics analysis reveals coordinated changes across MAPK, PI3K/Akt, and JAK-STAT signaling networks that drive the observed biological outcomes
For laboratory work, CJC-1295 No DAC are available from Proxiva Labs with ?98% HPLC-verified purity and comprehensive third-party documentation.
These findings demonstrate the multifaceted nature of CJC-1295 pain management research research and underscore the importance of rigorous experimental design. Future standardized protocols will be valuable for establishing reproducibility.
Key research includes work by Katsyuba & Auwerx, 2017, establishing critical parameters for understanding these mechanisms.
Frequently Asked Questions
What equipment is needed?
Standard molecular biology equipment including analytical balances, calibrated micropipettes, HPLC systems, and appropriate cell culture or animal facilities. Specialized endpoints may require plate readers, flow cytometers, or mass spectrometers.
Is this research clinically relevant?
While most CJC-1295 pain management research research is preclinical, translational potential is considerable. Related compounds have progressed through clinical trials. All Proxiva Labs peptides are strictly for laboratory research, not human consumption.
How long until results are visible?
Timelines vary by model and endpoint. In vitro changes appear within hours to days; in vivo outcomes require days to weeks. Chronic studies may extend months. Pilot studies to establish optimal timepoints are strongly recommended.
How should researchers study CJC-1295 pain management research?
Begin with thorough literature review to identify current protocols and validated outcomes. Standard approaches include in vitro cell culture, ex vivo tissue models, and in vivo animal studies with institutional ethical approval. Proper controls, randomization, and blinding are essential.
What mistakes should researchers avoid?
Common pitfalls: using compounds below 95% purity, failing to verify identity via mass spectrometry, inadequate sample sizes, and improper storage causing degradation. Always source from suppliers with verified purity documentation.
What is CJC-1295 pain management research?
Cjc-1295 pain management research encompasses a specific area of peptide science attracting significant research interest due to potential applications in biological research. Published studies document multiple evidence lines supporting its scientific significance, from molecular mechanisms to translational applications in preclinical models.
What does the research say about CJC-1295 pain management research?
Peer-reviewed literature on CJC-1295 pain management research spans multiple journals, providing growing evidence supporting continued investigation. Key findings include dose-dependent effects in preclinical models, characterized pharmacokinetic profiles, and favorable safety data within studied concentrations.
Where can I find high-quality research peptides?
Proxiva Labs offers research-grade peptides with ?98% HPLC purity and Certificates of Analysis. Independent third-party testing verifies identity, purity, and potency for reliable research results.
Related Research Resources
Explore more from Proxiva Labs:
- GHK-Cu (Copper Peptide) — a copper-binding tripeptide studied for skin remodeling and gene expression modulation
- SLU-PP-332 — an ERR alpha agonist studied as a potential exercise mimetic compound
- Semax — a synthetic ACTH analog studied for neuroprotective and cognitive effects
- TB-500 (Thymosin Beta-4) — a 43-amino acid peptide studied for tissue regeneration and anti-inflammatory effects
- Melanotan II — a synthetic melanocortin peptide studied for melanogenesis and photoprotection
- Browse All Research Guides
- Shop All Peptides
- Third-Party Test Results
Shop Research Peptides at Proxiva Labs
USA-Made • ?98% HPLC Purity • Third-Party Tested • Free Shipping $150+ • COA Included
a growth hormone releasing hormone analog studied for sustained GH elevation
a mitochondrial-derived peptide studied for metabolic regulation and exercise mi
a combination stack studied for synergistic tissue repair properties
a gastric pentadecapeptide studied for tissue repair and wound healing
an amino acid derivative studied for fatty acid transport and energy metabolism
a dual GIP/GLP-1 receptor agonist with emerging metabolic research applications
a proprietary peptide blend studied for skin health and rejuvenation